Table I.
Summary of Treatment Groups
| Group number |
Gonadal status |
S-4 (mg/day) |
DHT (mg/day) |
Bicalutamide (mg/day) |
|---|---|---|---|---|
| 1 | OVX | 0.1 | – | – |
| 2 | OVX | 0.3 | – | – |
| 3 | OVX | 0.5 | – | – |
| 4 | OVX | 0.75 | – | – |
| 5 | OVX | 1.0 | – | – |
| 6 | OVX | 3.0 | – | – |
| 7 | OVX | – | 1.0 | – |
| 8 | OVX | 0.5 | – | 1.0 |
| 9 | OVX | – | – | – |
| 10 | Intact | 1.0 | – | – |
| 11 | Intact | – | 1.0 | – |
| 12 | Intact | – | – | – |
Groups of animals (n = 10/group) were randomly assigned to receive the individual treatment(s) for 120 days. Doses (0.2 ml) were administered subcutaneously in a vehicle of DMSO and PEG300. Ovariectomy (OVX) was performed one day prior to the initiation of treatment.